SDC1 and Miyoshi myopathy: Nevertheless, intravenous injection of 213Bi-immunoconjugates targeting syndecan-1 (CD138), which is expressed at high levels in MM tumors within the bone marrow, was therapeutically effective in a murine MM model [36].